Last reviewed · How we verify
OctaplasLG®
OctaplasLG® is a liquid plasma product that replaces multiple coagulation factors and other plasma proteins to restore hemostatic function in patients with coagulation deficiencies.
OctaplasLG® is a liquid plasma product that replaces multiple coagulation factors and other plasma proteins to restore hemostatic function in patients with coagulation deficiencies. Used for Acute bleeding or perioperative bleeding in patients with multiple coagulation factor deficiencies, Reversal of vitamin K antagonist (warfarin) anticoagulation in emergency settings, Massive transfusion protocols.
At a glance
| Generic name | OctaplasLG® |
|---|---|
| Also known as | Octaplas, OctaplasLG |
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Plasma product; coagulation factor replacement |
| Target | Multiple coagulation factors (I, II, V, VII, VIII, IX, X, XI, XII) |
| Modality | Small molecule |
| Therapeutic area | Hematology; Hemostasis |
| Phase | FDA-approved |
Mechanism of action
OctaplasLG® is a solvent/detergent-treated pooled human plasma containing all major coagulation factors (I, II, V, VII, VIII, IX, X, XI, XII), fibrinolytic factors, and natural anticoagulants. It is used to rapidly correct multiple factor deficiencies in acute bleeding or perioperative settings where specific factor replacement is unavailable or impractical. The solvent/detergent treatment inactivates enveloped viruses, reducing transfusion-transmitted infection risk.
Approved indications
- Acute bleeding or perioperative bleeding in patients with multiple coagulation factor deficiencies
- Reversal of vitamin K antagonist (warfarin) anticoagulation in emergency settings
- Massive transfusion protocols
Common side effects
- Thromboembolic events (venous thromboembolism)
- Transfusion-related acute lung injury (TRALI)
- Allergic/anaphylactic reactions
- Hypervolemia/fluid overload
- Infection (viral/bacterial)
Key clinical trials
- Study Assessing Efficacy of Plasmatherapy in Septic Shock-induced Coagulopathy: Feasibility Study (NA)
- Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial (PHASE2)
- Observational Study of the Use of octaplasLG®.
- Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81) (PHASE4)
- Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |